Efficacy of Omalizumab in Indolent Systemic Mastocytosis

Table 1

Clinical characteristics and response to therapy of patients diagnosed with indolent systemic mastocytosis.

Patient #	Age	Gender	Disease duration	Optimal omalizumab dosage	Tryptase preomalizumab therapy	Tryptase during omalizumab therapy	Annualized frequency of anaphylaxis before treatment with omalizumab	Annualized frequency of anaphylaxis on optimal dose of omalizumab
1	38	M	10 years	150 mg·q. 4 weeks	134 ng/ml	84.1 ng/ml	2	2
2	51	F	3 years	300 mg·q. 4 weeks	11.4 ng/ml	8.3 ng/ml	60	0
3^1	55	F	4 years	300 mg·q. 2 weeks	31.8 ng/ml	N/A	—	—
4	42	F	2 years	300 mg·q. 4 weeks	55.2 ng/ml	61.7 ng/ml	1	0
5	42	M	10 years	300 mg·q. 4 weeks	42.2 ng/ml	34 ng/ml	1	0
6	75	F	3 years	300 mg·q. 4 weeks	40.5 ng/ml	36.8 ng/ml	1	0

¹This patient had poorly controlled manifestations of ISM but no history of anaphylaxis.